Etomidate, propofol and the neurosteroid THDOC increase the GABA efficacy of recombinant alpha4beta3delta and alpha4beta3 GABA A receptors expressed in HEK cells.
General anesthetics, once thought to exert their effects through non-specific membrane effects, have highly specific ion channel targets that can silence neuronal populations in the nervous system, thereby causing unconsciousness and immobility, characteristic of general anesthesia. Inhibitory GABA(A) receptors (GABA(A)Rs), particularly highly GABA-sensitive extrasynaptic receptor subtypes that give rise to sustained inhibitory currents, are uniquely sensitive to GABA(A)R-active anesthetics. A prominent population of extrasynaptic GABA(A)Rs is made up of alpha4, beta2 or beta3, and delta subunits. Considering the demonstrated importance of GABA receptor beta3 subunits for in vivo anesthetic effects of etomidate and propofol, we decided to investigate the effects of GABA anesthetics on "extrasynaptic" alpha4beta3delta and also binary alpha4beta3 receptors expressed in human embryonic kidney (HEK) cells. Consistent with previous work on similar receptor subtypes we show that maximal GABA currents through "extrasynaptic" alpha4beta3delta receptors, receptors defined by sensitivity to EtOH (30mM) and the beta-carboline beta-CCE (1microM), are enhanced by the GABA(A)R-active anesthetics etomidate, propofol, and the neurosteroid anesthetic THDOC. Furthermore, we show that receptors formed by alpha4beta3 subunits alone also show high GABA sensitivity and that saturating GABA responses of alpha4beta3 receptors are increased to the same extent by etomidate, propofol, and THDOC as are alpha4beta3delta receptors. Therefore, both alpha4beta3 and alpha4beta3delta receptors show low GABA efficacy, and GABA is also a partial agonist on certain binary alphabeta receptor subtypes. Increasing GABA efficacy on alpha4/6beta3delta and alpha4beta3 receptors is likely to make an important contribution to the anesthetic effects of etomidate, propofol and the neurosteroid THDOC.
Meera
Pratap
P
Department of Neurobiology, Geffen School of Medicine, University of California, Los Angeles, USA.
Olsen
Richard W
RW
Otis
Thomas S
TS
Wallner
Martin
M
D002461:Cell Line, Transformed; D002492:Central Nervous System Depressants / Q000494:pharmacology; D003900:Desoxycorticosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004558:Electric Stimulation / Q000379:methods; D000431:Ethanol / Q000494:pharmacology; D005045:Etomidate / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D018408:Patch-Clamp Techniques / Q000379:methods; D015742:Propofol / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000096:biosynthesis*; D014162:Transfection / Q000379:methods; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D002492:Central Nervous System Depressants; D006993:Hypnotics and Sedatives; D011963:Receptors, GABA-A; D011994:Recombinant Proteins; D000431:Ethanol; D003900:Desoxycorticosterone; C009413:tetrahydrodeoxycorticosterone; D005680:gamma-Aminobutyric Acid; D015742:Propofol; D005045:Etomidate
Mol Pharmacol. 2004 Oct;66(4):988-1003
15247320
J Neurosci. 2006 Mar 22;26(12):3357-64
16554486
Pharmacol Ther. 2007 Oct;116(1):7-19
17560657
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3662-7
14993607
Nat Neurosci. 2005 Mar;8(3):339-45
15696164
J Physiol. 2008 Feb 15;586(4):989-1004
18079158
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14066-71
9391153
J Neurochem. 2002 Jan;80(1):140-8
11796752
J Neurosci. 2006 Nov 8;26(45):11599-605
17093081
Curr Pharm Des. 2006;12(28):3665-79
17073666
Neuropharmacology. 2002 Sep;43(4):492-502
12367596
Nature. 1999 Jan 7;397(6714):69-72
9892355
Br J Pharmacol. 2008 Oct;155(3):424-33
18604239
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8546-51
16581914
Pharmacol Ther. 2006 Nov;112(2):513-28
16814864
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23
14625373
J Neurosci. 2005 Dec 14;25(50):11553-63
16354913
Epilepsy Curr. 2004 Nov-Dec;4(6):239-42
16059513
J Neurosci. 2004 Sep 22;24(38):8379-82
15385620
J Biol Chem. 2004 May 14;279(20):20982-92
15016806
Mol Pharmacol. 1996 Oct;50(4):931-8
8863839
J Biol Chem. 1999 Jul 9;274(28):19613-6
10391897
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11031-6
9380754
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15230-5
17005728
FASEB J. 2003 Feb;17(2):250-2
12475885
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7749-53
7644489
Neuron. 2007 Dec 6;56(5):851-65
18054861
Br J Pharmacol. 2008 Mar;153(5):1062-71
18204487
J Neurosci. 2002 Mar 1;22(5):1541-9
11880484
Nature. 1997 Sep 25;389(6649):385-9
9311780
Mol Pharmacol. 2004 Dec;66(6):1517-24
15331770
Neuropharmacology. 2000 Feb 14;39(4):611-20
10728882
J Neurosci. 2003 Nov 26;23(34):10934-43
14645489
Nat Neurosci. 2007 Jan;10(1):40-8
17159992
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8540-5
16698930
Pharmacol Biochem Behav. 2008 Jul;90(1):105-12
18201756
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44
14623958
Trends Neurosci. 2000 Sep;23(9):429-35
10941193
J Pharmacol Exp Ther. 2006 Oct;319(1):431-8
16844844
J Neurosci. 2003 Sep 17;23(24):8608-17
13679430
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12905-10
10536021
Alcohol. 2007 May;41(3):201-9
17591543
J Physiol. 2006 Dec 15;577(Pt 3):841-56
17023503
J Neurosci. 2008 Feb 6;28(6):1421-6
18256262